FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the ...
(Reuters) - An FDA advisory panel on Wednesday voted in favour of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex ...
The U.S. Food and Drug Administration approved the second drug to help prevent HIV infections on Thursday. Descovy is a PrEP or pre-exposure prophylaxis drug, which means the drug is taken daily to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results